Novo Nordisk's CagriSema shows blood pressure reduction in obesity trial
Go back to Novo Nordisk's CagriSema shows blood pressure reduction in obesity trial| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 43.07 -0.94 (2.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.01 | 52 Week High | $59.00 | |||
| Open | $43.19 | 52 Week Low | $32.80 | |||
| Day High | $43.50 | P/E | N/A | |||
| Day Low | $42.72 | EPS | $0.00 | |||
| Volume | 11,025,827 | |||||
